Fig. 9
CSF and plasma cytokines and resolvins in PD patients and control subjects. a Quantification with ELISA of CSF levels of pro- and anti-inflammatory cytokines in control subjects (CTRL) and PD patients (IFN-γ: 8 CTRL and 7 PD, P = 0.183; IL-1β: 6 CTRL and 7 PD, P > 0.999; IL-6: 8 CTRL and 7 PD, P = 0.467; TNF-α: 8 CTRL and 7 PD, P = 0.200; IL-4: 8 CTRL and 7 PD, **P = 0. 004; IL-10: 8 CTRL and 7 PD, P = 0. 294; IL-13: 8 CTRL and 7 PD, P = 0.436, all with Mann–Whitney test). b Quantification with ELISA of plasma levels of cytokines in CTRL and PD patients (IFN-γ: 8 CTRL and 7 PD, *P = 0.013; IL-1β: 6 CTRL and 7 PD, P = 0.169; IL-6: 8 CTRL and 7 PD, P > 0.999; TNF-α: 8 CTRL and 7 PD, P = 0.200; IL-4: 8 CTRL and 7 PD, P = 0.121; IL-10: 8 CTRL and 7 PD, *P = 0. 013; IL-13: 8 CTRL and 7 PD, P = 0.515, all with Mann–Whitney test). c Quantification of CSF and plasma levels of RvD1 in CTRL and PD patients (7 CTRL and 6 PD patients; CSF: *P = 0.049; Plasma: **P = 0.007, with two-tailed Welch’s t-test). d Quantification of CSF and plasma levels of RvD2 in PD and CTRL patients. No differences were detected between the two groups (CSF: 8 CTRL and 8 PD patients; P = 0.936; Plasma: 8 CTRL and 7 PD patients P = 0.667, with two-tailed Welch’s t-test). Source data are provided as a Source Data file
